-
1 Comment
Neuca S.A. is currently in a long term uptrend where the price is trading 18.0% above its 200 day moving average.
Neuca S.A.'s total revenue rose by 12.0% to $2B since the same quarter in the previous year.
Its net income has dropped by 27.4% to $18M since the same quarter in the previous year.
Finally, its free cash flow grew by 195.9% to $240M since the same quarter in the previous year.
Based on the above factors, Neuca S.A. gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Distribution |
| ISIN | PLTRFRM00018 |
| Exchange | WAR |
| CurrencyCode | PLN |
| PE Ratio | 20.57 |
|---|---|
| Target Price | 914 |
| Dividend Yield | 2.0% |
| Beta | 0.44 |
| Market Cap | 3B |
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company owns and produces Rx, OTC medicines, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brand names to pharmacists, medical doctors, and patients. It provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, stationary visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicine through apteline.pl, an e-commerce medical ordering site. Further, it engages in running clinical trials in the field of outsourcing clinical research and conducting clinical research centres; provision of insurance activities, including health insurance products. It also provides advertising and marketing services to pharmaceutical market entities; and logistics services for pharmaceutical manufacturers. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NEU.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
